Shares of Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) shot up 2.9% during trading on Monday . The stock traded as high as GBX 1,170 and last traded at GBX 1,135. 16,546 shares changed hands during trading, a decline of 55% from the average session volume of 37,068 shares. The stock had previously closed at GBX 1,102.50.
Hemogenyx Pharmaceuticals Price Performance
The stock has a market capitalization of £68.57 million, a PE ratio of -4.92 and a beta of 3.14. The company has a quick ratio of 6.72, a current ratio of 0.43 and a debt-to-equity ratio of -440.54. The stock’s 50-day moving average is GBX 779.54 and its 200 day moving average is GBX 809.38.
Hemogenyx Pharmaceuticals Company Profile
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
See Also
- Five stocks we like better than Hemogenyx Pharmaceuticals
- America’s 1776 happening again
- I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)
- Gilder: Don’t Buy AI Stocks, Do This Instead
- Your name isn’t on our protected list yet
- The Biggest IPO Ever… Open to Everyday Folks
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
